Targeting the PI3K/AKT/mTOR pathway: biomarkers of success and tribulation.
about
The PI3K/Akt Pathway in Tumors of Endocrine TissuesCerebellar Development and Autism Spectrum Disorder in Tuberous Sclerosis Complex.A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumorsMutation analysis of key genes in RAS/RAF and PI3K/PTEN pathways in Chinese patients with hepatocellular carcinoma.Comprehensive tumor profiling identifies numerous biomarkers of drug response in cancers of unknown primary site: analysis of 1806 cases.Quantitative phosphoproteomic analysis identifies activation of the RET and IGF-1R/IR signaling pathways in neuroblastoma.A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non-Small Cell Lung CancerMicroRNA-451 regulates stemness of side population cells via PI3K/Akt/mTOR signaling pathway in multiple myeloma.Comparison of Equivalence between Two Commercially Available S499-Phosphorylated FMRP Antibodies in MiceMultiple Mechanisms of Anti-Cancer Effects Exerted by Astaxanthin.VEGF-A/NRP1 stimulates GIPC1 and Syx complex formation to promote RhoA activation and proliferation in skin cancer cells.Expression of PI3Kp110α and PI3Kp110β in the colorectal conventional adenoma, serrated lesions and adenoma with canceration and their significanceResveratrol analogue 3,4,4'-trihydroxy-trans-stilbene induces apoptosis and autophagy in human non-small-cell lung cancer cells in vitro.Tuberous Sclerosis and Bilateral Renal Angiomyolipomas: A Case Report and Literature Review of Emerging Treatment StrategiesPKG II reverses HGF-triggered cellular activities by phosphorylating serine 985 of c-Met in gastric cancer cells.The Epstein Barr-encoded BART-6-3p microRNA affects regulation of cell growth and immuno response in Burkitt lymphomaBiomarkers of drugs targeting HER-family signalling in cancer.The role of the dysfunctional akt-related pathway in cancer: establishment and maintenance of a malignant cell phenotype, resistance to therapy, and future strategies for drug development.Targeting the PI3K/AKT/mTOR pathway: potential for lung cancer treatmentSomatic overgrowth disorders of the PI3K/AKT/mTOR pathway & therapeutic strategies.PIK3CA and PIK3CB silencing by RNAi reverse MDR and inhibit tumorigenic properties in human colorectal carcinoma.Metformin in pancreatic cancer treatment: from clinical trials through basic research to biomarker quantification.Vertical Targeting of AKT and mTOR as Well as Dual Targeting of AKT and MEK Signaling Is Synergistic in Hepatocellular Carcinoma.Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2- Advanced Breast Cancer.Whey Protein Concentrate Renders MDA-MB-231 Cells Sensitive to Rapamycin by Altering Cellular Redox State and Activating GSK3β/mTOR Signaling.Oxygen- and temperature-dependent expression of survival protein kinases in crucian carp (Carassius carassius) heart and brain.Interactions of Alphavirus nsP3 Protein with Host Proteins.Four PTEN-targeting co-expressed miRNAs and ACTN4- targeting miR-548b are independent prognostic biomarkers in human squamous cell carcinoma of the oral tongue.Negative regulators of cell death pathways in cancer: perspective on biomarkers and targeted therapies.Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing.Inhibitors of mTOR pathway for cancer therapy, moving on from rapalogs to TORKinibs.The role of miR-106p-5p in cervical cancer: from expression to molecular mechanismGlobal Approaches to Understanding Protein Kinase FunctionsNew Insights into the Role of Exercise in Inhibiting mTOR Signaling in Triple-Negative Breast Cancer
P2860
Q26770404-20D51B62-B602-4FA8-91D7-FA881D69323DQ30989503-6E2CD468-A5C2-436A-A4C1-41011CEB3E54Q33435808-CAE74189-8480-423D-B71F-AA623050ACB6Q33968053-45550F52-18AB-4537-BD0B-0145D46F0FA1Q35068021-834C06B3-6561-4BFD-8603-44C1586CAA64Q35070321-A92CDF99-45F6-4BE8-BD7B-A258DF10137CQ35463464-77B389B1-5DCE-40CA-9495-5016A48E885DQ35615252-243A98B3-309D-4FCA-A945-78CED5A2AA64Q35844954-6DA93612-C3FB-4921-BBDE-AD03F81B015FQ35890732-A4A547C7-5713-4DFB-B9D0-DD81235CC170Q36090874-58613215-74D2-4138-9DDC-BDB14A825F66Q36511817-70D0244F-FBD0-4B7F-968E-6F82786D5134Q36746148-EE2081C3-C619-42F7-B48C-F1B2E7132A58Q37156911-E66264CF-87C5-493B-B037-4D29481DABA5Q37376230-5677A92E-8B3A-4B54-8F8D-ABE9982F577AQ37733947-08CF665A-C05B-4D44-B7AA-25969151115FQ38150774-8F15617F-9C81-4922-8C47-6CE2B244E49CQ38175044-95E206F6-4205-4B83-9557-39D01E32957DQ38262500-50B23B81-975D-4916-AD89-BAD9A83E2B82Q38793867-00F881F3-5863-448F-AA96-77F50FC9EAE7Q38805492-F8E0C33F-59E1-4431-9875-890B04D3DCAFQ38829871-B2F0D90A-EF86-4615-AA91-CBABE527EB2EQ38946509-FEBB10AD-F305-45C6-8E9B-36DF3ECF99DAQ39172983-63E2458B-0F92-4250-B0F4-CD65D471D06FQ46256792-9272BF1C-721D-413F-B346-C9E30B1BE76AQ46817106-36C8C7C1-B2C2-43FB-B2EA-24065FF7A337Q47548511-B9E6DA6A-75BB-441D-8F7D-F5F2F74F031FQ47988269-5D0D2677-B3DD-4294-BC0C-F0BDB27696B1Q50097295-85568BBC-4DCA-4761-99FC-7CBF27F13296Q52571727-D5F47F96-1306-4A1C-92DC-57E4F16638DEQ55053118-8F5C8555-5590-4D7B-AD3E-CB8967C2F124Q57071744-B5951971-9E05-42A4-96FB-55EA49DD9061Q57833109-538BD28F-340C-460C-A784-C61E0C523D1BQ58200565-42D97C55-53D5-4A50-AE1B-1B5E1E105686
P2860
Targeting the PI3K/AKT/mTOR pathway: biomarkers of success and tribulation.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Targeting the PI3K/AKT/mTOR pathway: biomarkers of success and tribulation.
@en
type
label
Targeting the PI3K/AKT/mTOR pathway: biomarkers of success and tribulation.
@en
prefLabel
Targeting the PI3K/AKT/mTOR pathway: biomarkers of success and tribulation.
@en
P2860
P1476
Targeting the PI3K/AKT/mTOR pathway: biomarkers of success and tribulation.
@en
P2093
Fadlo R Khuri
Taofeek K Owonikoko
P2860
P356
10.1200/EDBOOK_AM.2013.33.E395
P577
2013-01-01T00:00:00Z